Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)

  • Justin Moser1
  • Jose Lutzky2
  • Andrew Elliott3
  • Yasmine Baca4
  • Nishant Gandhi5
  • Poorva Vaidya6
  • Gino K In7
  • Clara J Oh8
  • Jingshu Chen9
  • Garrett Kraft10
10 affiliations
  1. 17 HonorHealth Research Institute, Scottsdale, Arizona, USA
  2. 2University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA
  3. 3Caris Life Sciences Inc Arizona Office/Labs, Phoenix, Arizona, USA
  4. 4Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona, USA
  5. 53 Clinical & Translational Research, Medical Affairs, Caris Life Sciences, Caris Life Sciences, Phoenix, Arizona, USA
  6. 65UCI Health Chao Family Comprehensive Cancer Center, Irvine, CA, USA
  7. 7USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
  8. 8University of Miami, Miami, FL, USA
  9. 9CARIS Life Sciences, Phoenix, AZ, USA
  10. 10University of Miami - School of Medicine, Miami, FL, USA
Open at sourcePDFDOICite

Related

  1. Spatial confinement induces oscillatory migration of epidermal keratinocytes and forms a three-compartment epithelial structure with epithelial–mesenchymal transition dynamics
    Takuma Nohara, Sota Itamoto, Junichi Kumamoto +11
    eLifePeer-reviewedCC BY 4.0Full textCell biologyDevelopmental biologyeLife
  2. Lack of centrosomes limits the epithelial-to-mesenchymal transition in human mammary cells
    M. L. Pigazzini, J. M. Tocci, M. Boulanger +4
    bioRxivPreprintCC BYFull textCell biologybioRxiv
  3. Cell cycling throttles epithelial--mesenchymal transition
    M. McDermott, A. Dey, R. Mehta +1
    bioRxivPreprintCC BY-NCFull textSystems & synthetic biologybioRxiv
  4. Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis
    Rui Fan, Ying Liu, Guodong Zang +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefPMC
  5. DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
    Julie Dardare, Andréa Witz, Margaux Betz +11
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full text19 citedProteomics & metabolomicsGeneral biologyHAL

Cite

BibTeXRIS
BibTeX
@article{moser2026cxcl6,
  title = {{114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)}},
  author = {Justin Moser and Jose Lutzky and Andrew Elliott and Yasmine Baca and Nishant Gandhi and Poorva Vaidya and Gino K In and Clara J Oh and Jingshu Chen and Garrett Kraft},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0114},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0114},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)
AU  - Justin Moser
AU  - Jose Lutzky
AU  - Andrew Elliott
AU  - Yasmine Baca
AU  - Nishant Gandhi
AU  - Poorva Vaidya
AU  - Gino K In
AU  - Clara J Oh
AU  - Jingshu Chen
AU  - Garrett Kraft
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0114
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0114
SN  - 2051-1426
ER  -